Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–28 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic HER2 Positive Gastroesophageal Junction Cancer Clear all
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
Interventions
CAM-H2
Drug
Lead sponsor
Precirix
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Duarte, California • Stanford, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced May 22, 2026, 1:08 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Interventions
Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil, Oxaliplatin, Zolbetuximab, Leucovorin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
69
States / cities
Phoenix, Arizona • Springdale, Arkansas • Duarte, California + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 1:08 AM EDT